


AAF-CMK

Cat. No.:	HY-129407A
CAS No.:	102129-66-8
Molecular Formula:	C ₁₆ H ₂₂ ClN ₃ O ₃
Molecular Weight:	339.82
Target:	Ser/Thr Protease; Apoptosis
Pathway:	Metabolic Enzyme/Protease; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	AAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research ^[1] .																
In Vitro	<p>AAF-CMK (0-20 μM; 24 h) shows potentiated antitumor effects of U937 leukemia cells in combination with TRAIL or TNF^[1]. AAF-CMK (20 μM; 24 h) increases TNF- and TRAIL-induced U937 cell apoptosis^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>U937 human promonocytic leukemia cells</td> </tr> <tr> <td>Concentration:</td> <td>0-20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Resulted in the potentiation of growth inhibitory cytostatic effects of TRAIL as well as TNF.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>U937 human promonocytic leukemia cells</td> </tr> <tr> <td>Concentration:</td> <td>20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Increased the percentage of apoptotic cells to 55.8% in combination with TRAIL. Increased number of cells with characteristic apoptotic morphology in groups treated with AAF-CMK and both TRAIL or TNF compared to each group treated alone.</td> </tr> </table>	Cell Line:	U937 human promonocytic leukemia cells	Concentration:	0-20 μM	Incubation Time:	24 h	Result:	Resulted in the potentiation of growth inhibitory cytostatic effects of TRAIL as well as TNF.	Cell Line:	U937 human promonocytic leukemia cells	Concentration:	20 μM	Incubation Time:	24 h	Result:	Increased the percentage of apoptotic cells to 55.8% in combination with TRAIL. Increased number of cells with characteristic apoptotic morphology in groups treated with AAF-CMK and both TRAIL or TNF compared to each group treated alone.
Cell Line:	U937 human promonocytic leukemia cells																
Concentration:	0-20 μM																
Incubation Time:	24 h																
Result:	Resulted in the potentiation of growth inhibitory cytostatic effects of TRAIL as well as TNF.																
Cell Line:	U937 human promonocytic leukemia cells																
Concentration:	20 μM																
Incubation Time:	24 h																
Result:	Increased the percentage of apoptotic cells to 55.8% in combination with TRAIL. Increased number of cells with characteristic apoptotic morphology in groups treated with AAF-CMK and both TRAIL or TNF compared to each group treated alone.																

REFERENCES

[1]. Młnarczuk I, et al. AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. Leuk Res. 2004 Jan;28(1):53-61.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA